معرفی
Sarah Jones is an Associate Professor (Research) in the Department of Medicine, School of Clinical Sciences at Monash Health, Monash University. She leads the Rheumatology Research Laboratory and is actively involved in pre-clinical and clinical research on autoimmune diseases, particularly systemic lupus erythematosus (SLE). She also serves as Founder and acting CEO of GILZRx Pty Ltd, translating her research into therapeutic development.
Her research focuses on understanding the mechanisms of autoimmune diseases and developing alternatives to glucocorticoids by targeting the glucocorticoid-induced protein GILZ. Her team leverages lupus models, human immunology, and a large longitudinal clinical database linked to a biobank. Key research areas include:
- Immunology of B and T cells in autoimmunity
- Type I interferon signaling
- Autophagy in inflammation
- Clinical translation and drug discovery
Her recent publications highlight a strong trend in understanding interferon pathways in SLE, the role of GILZ in immune regulation, and myeloid cell autophagy in chronic inflammation. These works reflect a cohesive research program aiming at safer, targeted therapies for autoimmune conditions.
She has been recognized with the veski Inspiring Women Career Recovery Grant, supporting her independent research and commercialization efforts. Her projects include major investigations into next-generation glucocorticoid replacements and academic-industry collaborations.
Sarah supervises a diverse team of researchers, including PhD and MD-PhD students, and is committed to mentoring the next generation, especially women in science. She also contributes significantly to secondary education as scientific consultant, editor, and lead author of Nelson Cengage Learning’s senior biology textbooks in Australia and New Zealand. Her lab includes a postdoctoral researcher and six PhD students, all women, reflecting her dedication to equity and leadership development.
She leads active research projects such as:
- Achieving benefit without harm: a next-generation glucocorticoid replacement (2022–2025)
- Regulation of cytotoxic T cells in immunity and autoimmunity
- Academic/Industry collaboration on corticosteroids and TLR7/8 inhibitors
حوزههای پژوهشی
